Actively Recruiting

Phase Not Applicable
Age: 3Weeks - 12Weeks
All Genders
NCT07190859

Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

Led by BioGaia AB · Updated on 2025-09-24

50

Participants Needed

4

Research Sites

55 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying and fussing time.

CONDITIONS

Official Title

Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

Who Can Participate

Age: 3Weeks - 12Weeks
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. Aged between 3-12 weeks at screening.
  2. Gestational age 37+0 weeks - 42+0 weeks at birth.
  3. Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.
  4. Parents/caregivers/legal guardians are >18 years.
  5. Exclusively or predominantly breastfed infants (> 50 % breast fed).
  6. Willing to maintain current feeding patterns (not change formula/not change ratio of formula:breast milk etc.).
  7. Readiness and the opportunity for parents/caregivers/legal guardians to fill out a study diary, questionnaires.
  8. Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents/caregivers/legal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hour period should show 3 or more hours of crying/fussing time.
  9. Parents/caregivers/legal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator.
  10. Parents/caregivers/legal guardians willing and able to give informed consent for their and their infant's participation in the study.
  11. The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 3 (Day 8), and Visit 4 (Day 22).
  12. Infant is considered healthy, in the opinion of the investigator following physical exam.
Not Eligible

You will not qualify if you...

  1. Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk > 8 times daily, projectile, bilious or bloody emesis).
  2. Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container > 12x in breastfed and >5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents/caregivers/ legal guardians.
  3. Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.
  4. Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.
  5. Infants with reported exposure to oral and/or systemic antibiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.
  6. Infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to Screening Visit (V1) and throughout the study period.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

UMHAT Deva Maria

Burgas, Bulgaria, 8127

Actively Recruiting

2

Medical Centre Asklepiy OOD

Dupnitsa, Bulgaria, 2600

Actively Recruiting

3

AIPSMP

Stara Zagora, Bulgaria, 6000

Actively Recruiting

4

Ipsmp Eood

Stara Zagora, Bulgaria, 6000

Actively Recruiting

Loading map...

Research Team

S

Sanna Nyström, PhD

CONTACT

P

Petra J Lierud

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic | DecenTrialz